文献速递消化系统肿瘤

间歇或持续帕尼单抗联合氟尿嘧啶、亚叶酸和伊立替康一线治疗RAS与BRAF野生型转移性结直肠癌:IMPROVE试验

Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial.
PubMed 文献 · J Clin Oncol · 2024-11-22

IMPROVE是一项开放标签、多中心、随机II期非比较试验,纳入不可切除的RAS/BRAF野生型转移性结直肠癌患者,随机分配接受持续或间歇FOLFIRI联合帕尼单抗治疗。间歇治疗组12个月治疗中无进展生存率为58.5%,持续治疗组为45.7%,且间歇组帕尼单抗相关>2级皮肤不良事件发生率更低。

要点

  • 间歇FOLFIRI联合帕尼单抗在诱导期后可行,主要终点达到。
  • 间歇组12个月PFSot率为58.5%,持续组为45.7%。
  • 间歇组帕尼单抗相关>2级皮肤不良事件发生率17.9%,持续组为30.3%。

核心结论

  • 诱导期后间歇FOLFIRI联合帕尼单抗治疗可行,主要终点达到,且毒性降低,允许患者有更多治疗间歇时间。

研究设计与样本

  • IMPROVE为开放标签、多中心、随机II期非比较试验(ClinicalTrials.gov标识:NCT04425239)。
  • 不可切除的RAS/BRAF野生型转移性结直肠癌患者按1:1随机分配至持续FOLFIRI联合帕尼单抗治疗至进展(A组)或间歇治疗伴无治疗间期(B组)直至治疗中进展、毒性或死亡。
  • 主要终点为12个月时的治疗中无进展生存(PFSot)。
  • 假设中位PFSot≤7个月且目标PFSot≥10个月,根据二项检验,每组需65例患者以达到80%把握度和10%I类错误。
  • 2018年5月至2021年6月间,69例患者随机分配至A组,68例至B组。

主要发现

  • A组中位治疗周期数为13,B组为16。
  • 中位随访43.2个月(IQR,35.0-50.5)时,A组和B组的中位PFSot分别为11.2个月和17.5个月,12个月PFSot率分别为45.7%和58.5%。
  • A组和B组的总体缓解率分别为68.1%和61.2%,中位总生存期分别为36.3个月和35.1个月。
  • 帕尼单抗相关>2级皮肤不良事件的总体发生率在A组为30.3%,在B组为17.9%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate whether intermittent treatment after an induction phase of first-line schedule of fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus panitumumab (PAN) prevents or delays the onset of resistance and improves safety and compliance with treatment in patients with unresectable RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: IMPROVE (ClinicalTrials.gov identifier: NCT04425239) was an open-label, multicenter, randomized phase II noncomparative trial. Patients with unresectable RAS/BRAF wt mCRC were randomly assigned (1:1) to receive FOLFIRI plus PAN continuously until progression (arm A) or intermittently, with treatment-free intervals (arm B) until progression on treatment, toxicity, or death. The primary end point was progression-free survival on treatment (PFSot) at 12 months. Assuming a null hypothesis of median PFSot time ≤7 months and target PFSot ≥10 months, 65 patients per arm were needed to achieve 80% power and 10% type I error, according to the binomial test. RESULTS: Between May 2018 and June 2021, 69 patients were randomly assigned to arm A and 68 to arm B. The median number of treatment cycles was 13 in arm A and 16 in arm B. At a median follow-up of 43.2 months (IQR, 35.0-50.5), median PFSot was 11.2 and 17.5 months with 12-month PFSot rates of 45.7% and 58.5%, for arms A and B, respectively. The overall response rates were 68.1% and 61.2%, and median overall survival rates were 36.3 and 35.1 months in arms A and B, respectively. The overall rate of grade >2 skin PAN-related adverse events was 30.3% in arm A and 17.9% in arm B. CONCLUSION: Intermittent FOLFIRI plus PAN after the induction phase was feasible, and the primary end point was met with reduced toxicity while allowing patients more time off treatment.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Avallone A, Giuliani F, De Stefano A, et al. Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial. J Clin Oncol. 2024. PMID: 39576946. doi:10.1200/JCO.24.00979

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。